Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) was the target of a large decrease in short interest during the month of July. As of July 31st, there was short interest totaling 3,603 shares, a decrease of 86.4% from the July 15th total of 26,584 shares. Based on an average daily trading volume, of 47,927 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are sold short.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on NVZMY shares. Kepler Capital Markets upgraded Novozymes A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Zacks Research upgraded Novozymes A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Two investment analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Novozymes A/S has a consensus rating of “Buy”.
Read Our Latest Stock Report on Novozymes A/S
Novozymes A/S Stock Performance
About Novozymes A/S
Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.
The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).
See Also
- Five stocks we like better than Novozymes A/S
- Fastly’s Q2 Rally Shows Investors Are Buying the Edge AI Turnaround
- Paramount’s 30-Film Promise Puts AMC Back in the Box Office Conversation
- DraftKings’ Predictions Push Could Be the Bet That Matters Most
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.
